Background: Cetuximab, an epidermal growth factor receptor (EGFR)-targeting antibody,
remains the only Food and Drug Administration-approved targeted therapy for squamous …

Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a
monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to …

Background The aims of this study were to validate in vitro drug sensitivity testing of head
and neck squamous cell carcinoma (HNSCC) cell lines in an in vivo xenograft model and to …

BACKGROUND: The phase III EXTREME and CRYSTAL studies demonstrated that the
addition of cetuximab to chemotherapy significantly improved survival in the first-line …

Head and neck cancer is the sixth most common cancer worldwide. At present, globally
about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are …

Objective The aim of this study was to investigate the effect of epidermal growth factor
receptor (EGFR) blockade on cell survival and on downstream signalling pathways using …

We sought to identify biomarkers of antitumor activity in patients with locally advanced head
and neck cancer treated with therapy containing cetuximab, an epidermal growth factor …

Background Cetuximab is a targeted therapy with demonstrated efficacy in the management
of head and neck squamous cell carcinoma (HNSCC). However, no laboratory assay is …

Squamous cell carcinomas (SCC) arising in upper parts of the aerodigestive tract are among
the leading causes of death worldwide. EGFR has been found to play an essential role in …

Importance of the field: Head and neck squamous cell carcinoma (HNSCC) is the eighth
leading cause of cancer death worldwide. Despite advances in surgery and chemoradiation …